Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 511 to 520 of 1514 total matches.

Arrhythmias From Droperidol?

   
The Medical Letter on Drugs and Therapeutics • Jun 10, 2002  (Issue 1132)
Letter, Inc. • 1000 Main Street, New Rochelle, N.Y. 10801 • A Nonprofit Publication Vol. 44 (W1132C ...
The FDA has added a "black box" warning about the risks of QT prolongation and the potentially fatal torsades de pointes (TdP) ventricular tachycardia to the labeling of droperidol (Inapsine - Akorn), an antiemetic used mostly in anesthesia. The Canadian Health Protection Branch has issued a similar warning. Some anesthesiologists have written to The Medical Letter to express their displeasure with these warnings.
Med Lett Drugs Ther. 2002 Jun 10;44(1132):53-4 |  Show IntroductionHide Introduction

Beta Interferons for Multiple Sclerosis

   
The Medical Letter on Drugs and Therapeutics • Oct 14, 2002  (Issue 1141)
Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication Vol. 44 (W1141B ...
Three beta interferons are widely used in the treatment of patients with relapsing-remitting multiple sclerosis (RRMS).
Med Lett Drugs Ther. 2002 Oct 14;44(1141):88-9 |  Show IntroductionHide Introduction

Rasburicase (Elitek) for Hyperuricemia

   
The Medical Letter on Drugs and Therapeutics • Nov 11, 2002  (Issue 1143)
Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication Vol. 44 (W1143B ...
Rasburicase (Elitek - Sanofi-Synthelabo), a recombinant form of urate oxidase derived from the fungus Aspergillus flavus, has been approved by the FDA for intravenous (IV) management of hyperuricemia associated with tumor lysis syndrome in pediatric patients.
Med Lett Drugs Ther. 2002 Nov 11;44(1143):96-7 |  Show IntroductionHide Introduction

OTC loratadine (Claritin)

   
The Medical Letter on Drugs and Therapeutics • Jan 06, 2003  (Issue 1147)
Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication Vol. 45 (W1147B ...
The FDA has approved the marketing of loratadine (Claritin - Schering), a second-generation H1-antihistamine, without a prescription. The drug was also recently approved for OTC use as Alavert (Wyeth) and other generics are expected.
Med Lett Drugs Ther. 2003 Jan 6;45(1147):3-4 |  Show IntroductionHide Introduction

Anastrozole (Arimidex) vs. Tamoxifen for Treatment of Early Breast Cancer

   
The Medical Letter on Drugs and Therapeutics • Mar 17, 2003  (Issue 1152)
Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication Vol. 45 (W1152B ...
Anastrozole (Arimidex - AstraZeneca, Medical Letter 1996; 38:61), an aromatase inhibitor, has received accelerated approval from the FDA for adjuvant treatment of postmenopausal women with early hormone-receptor-positive breast cancer. The drug was approved for treatment of postmenopausal women with metastatic breast cancer in 1996.
Med Lett Drugs Ther. 2003 Mar 17;45(1152):22-3 |  Show IntroductionHide Introduction

Drug-eluting Stents

   
The Medical Letter on Drugs and Therapeutics • Mar 17, 2003  (Issue 1152)
Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication Vol. 45 (W1152C ...
Most angioplasty procedures for coronary artery disease now include placement of stents, which have improved both short- and long-term success rates. The main limitation is restenosis, which occurs in about 25% of patients. Drug-eluting stents intended to reduce the incidence of restenosis have been approved for use in Europe, but not yet in the US.
Med Lett Drugs Ther. 2003 Mar 17;45(1152):23-4 |  Show IntroductionHide Introduction

Blue light (ClearLight) for Acne Vulgaris

   
The Medical Letter on Drugs and Therapeutics • Jun 23, 2003  (Issue 1159)
Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication Vol. 45 (W1159B) June ...
A high-intensity, narrow-band blue light (ClearLight -Lumenis) approved by the FDA for treatment of moderate inflammatory acne vulgaris has been featured in some stories in fashion magazines. This review describes the etiology and treatment of acne, as well as the mechanism of action, clinical studies, adverse effects, dosage and cost of the drug.
Med Lett Drugs Ther. 2003 Jun 23;45(1159):50-1 |  Show IntroductionHide Introduction

Over-the-counter Omeprazole (Prilosec OTC)

   
The Medical Letter on Drugs and Therapeutics • Aug 04, 2003  (Issue 1162)
Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication Vol. 45 (W1162A ...
The FDA recently approved the proton pump inhibitor omeprazole magnesium (Prilosec OTC) for over-the-counter use for treatment of frequent heartburn. It will be marketed in late September or early October. Five proton pump inhibitors, including omeprazole, are available by prescription in the US (Medical Letter 2001; 43:36).
Med Lett Drugs Ther. 2003 Aug 4;45(1162):61-2 |  Show IntroductionHide Introduction

Private Cord Blood Banks

   
The Medical Letter on Drugs and Therapeutics • Mar 15, 2004  (Issue 1178)
Letter, Inc. 1000 Main Street, New Rochelle, NY 10801 A Nonprofit Publication Vol. 46 (Issue 1178 ...
Private cord blood banks continue to advertise their services to couples expecting a child. Cord blood can be stored safely for many years. Public cord blood banks accept collections only from affiliated hospitals (Medical Letter 2001; 43:84). Units are available for any patient; there is no guarantee that a particular donor's blood will be available if the donor or a family member needs a stem cell transplant. Many patients can find an unrelated match in a public cord blood bank, but members of minority ethnic groups are often more difficult to match (www.marrow.org). Private cord blood banks...
Med Lett Drugs Ther. 2004 Mar 15;46(1178):21-2 |  Show IntroductionHide Introduction

Olanzapine/Fluoxetine (Symbyax) for Bipolar Depression

   
The Medical Letter on Drugs and Therapeutics • Mar 15, 2004  (Issue 1178)
, New Rochelle, NY 10801 A Nonprofit Publication Vol. 46 (Issue 1178) March 15, 2004 EDITOR: Mark ...
The fixed-dose combination of olanzapine and fluoxetine (Symbyax - Lilly) has been approved by the FDA for treatment of depressive episodes associated with bipolar disorder. Olanzapine alone (Zyprexa), which is mainly used as an antipsychotic (Medical Letter 2003; 45:102), is FDA-approved for treatment of acute manic episodes and for maintenance treatment of bipolar disorder. Fluoxetine alone (Prozac, and others), which is mainly used as an antidepressant (Medical Letter 2003; 45:93), has no specific approval for use in bipolar...
Med Lett Drugs Ther. 2004 Mar 15;46(1178):23-4 |  Show IntroductionHide Introduction